Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Esomeprazole Stories

2014-03-28 12:26:09

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/lj5htc/investigation) has announced the addition of the "Investigation Report on China's Esomeprazole Market, 2009-2018" [http://www.researchandmarkets.com/research/lj5htc/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Digestive system disease is one of the most frequently occurring diseases....

2013-12-12 20:24:59

ZURICH, December 12, 2013 /PRNewswire/ -- - First Head to Head Study Showed Tecta(R) As Effective for Healing and Complete Remission of Erosive GERD with Significantly Higher Symptom Relief After 8 Weeks compared to Esomeprazole[1] - Takeda Pharmaceuticals International GmbH (Takeda) announced today results showing pantoprazole magnesium 40 mg (Tecta(R)) was as effective as esomeprazole 40 mg for achieving complete remission...

2013-10-02 23:29:41

d'Oliveira & Associates has posted a new infographic about the proton pump inhibitor (PPI) Prilosec. The law firm works with some of the more experienced Prilosec lawyers, who handle these cases. (PRWEB) October 02, 2013 Prilosec (omeprazole) is included in the proton pump inhibitor (PPI) class of drugs. These drugs are used to heart burn and related conditions like dyspepsia, peptic ulcer disease (PUD), and gastroesophageal reflux disease (GERD). In May 2010, the FDA warned...

2013-09-19 08:25:17

NEW YORK, September 19, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Investors' Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), GlaxoSmithKline plc (NYSE: GSK), Sanofi SA (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), and Neurocrine Biosciences, Inc. (NASDAQ: NBIX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst...

2013-07-15 12:25:24

NEXIUM YouTube Channel Provides Information on Acid Reflux Disease, Symptom Relief and Savings WILMINGTON, Del., July 15, 2013 /PRNewswire/ -- Acid reflux disease, also known as gastroesophageal reflux disease (GERD), is one of the most common chronic illnesses in the US today, affecting more than 60 million Americans each month.(1 )To help educate consumers about NEXIUM, a prescription treatment option for those diagnosed with GERD, as well as support and empower those living with...

2013-05-06 08:30:49

NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs. (Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-a )(Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-b ) The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's leading acid blocker,...

2013-03-22 23:03:16

Court data updated on March 5th, 2013, by the US Judicial Panel on Multi-District Litigation (MDL), indicate that there are 42 actions currently pending in the Nexium MDL. In light of these news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Nexium side effects. San Diego, CA (PRWEB) March 22, 2013 AttorneyOne.com, a recognized authority on law, updated the website...

2013-03-18 23:02:23

The law firm of d´Oliveira & Associates, has announced a “No Win — No Fee Promise” to any clients that have suffered any of the side effects of Prilosec and may be entitled to compensation. (PRWEB) March 18, 2013 Originally put on the market in 1989 by AstraZeneca, Prilosec is a member of a class of drugs called Proton Pump Inhibitors (PPIs). These drugs (including popular drugs Prilosec and Nexium) have been linked to loss of bone density in patients similar to...

2013-02-21 08:30:44

ST. PAUL, Minn., Feb. 21, 2013 /PRNewswire/ -- For the millions who suffer from Gastroesophageal Reflux Disease (GERD), a study published today in the New England Journal of Medicine (NEJM) provides clinical evidence of safety and effectiveness for a new, FDA-approved medical device. Torax Medical's LINX(®) Reflux Management System was studied in a controlled, prospective, multicenter trial involving 14 U.S. and European medical centers as part of the FDA pre-market approval process....

2013-02-11 12:23:05

BERKELEY HEIGHTS, N.J., Feb. 11, 2013 /PRNewswire/ -- MedAccess, an Access Group Company, graced the cover of the January issue of PM360 as the overall "grand tier" winner of the Pharma Choice Awards, netting a gold in the coveted branded print ad category. The Access Group was also awarded an additional gold and a silver. PM360, a leading health-marketing industry trade magazine, recognizes the best print and digital campaigns in the industry. All submissions are placed online, where...